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Abstract: 
Small-molecule kinase inhibitors are invaluable targeted therapeutics for the treatment of various 
human diseases, especially cancers. While the majority of approved and developed preclinical 
small-molecule inhibitors are characterized as type I or type II inhibitors that target the ATP-
binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets 
renders the selective inhibition of kinases a daunting challenge. Therefore, targeting allosteric 
pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising 
alternative to overcome current barriers of kinase inhibitors, including poor selectivity and 
emergence of drug resistance.  In spite of the small number of identified allosteric inhibitors in 
comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-
approval of the first small-molecule allosteric inhibitor trametinib in 2013, the progress of more 
than 10 other allosteric inhibitors in clinical trials, and the emergence of a pipeline of highly 
selective and potent preclinical molecules, have been reported in the past decade. In this article, we 
present the current knowledge on allosteric inhibition in terms of conception, classification, 
potential advantages, and summarized debatable topics in the field. Recent progress and allosteric 
inhibitors that were identified in the past three years are highlighted in this paper. 
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List of Abbreviations: 
AGC, containing protein kinase A, protein kinase G, protein kinase C families; 
ATP, adenosine 5’-triphosphate; 
CAMK, calcium/calmodulin-dependent protein kinases; 
CDK, cyclin-dependent kinase; 
CHK1, checkpoint kinase 1; 
CMKC, containing CDK, MAPK, GSK3, CLK families; 
DFG, aspartate-phenylalanine-glycine residues; 
FAK, focal adhesion kinase; 
FDA, United States Food and Drug Administration; 
IGF-1R, insulin-like growth factor-1 receptor; 
IKK, IκB kinase; 
IRE1, inositol requiring enzyme 1; 
ITK, interleukin-2-inducible T-cell kinase; 
JNK, c-Jun N-terminal kinase; 
LIMK, LIM (Lin11, Isl1 & Mec3) domain-containing kinase; 
MAPK, mitogen-activated protein kinase (also known as ERK, extracellular signal-regulated 
kinase); 
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MAPKK, mitogen-activated protein kinase kinase (also known as MEK, mitogen/extracellular 
signal-regulated kinase); 
mTOR, mammalian target of rapamycin; 
NSCLC, non-small cell lung cancer; 
PAK1, p21-activated kinase 1; 
PDK1, phosphoinositide-dependent kinase1; 
PH domain, pleckstrin homology domain; 
PIF, PDK1-interacting fragment; 
PI3K, phosphatidylinositol 3-kinase; 
PIKK, phosphatidylinositol 3-kinase-like protein kinases; 
PKB, protein kinase B (also known as Akt); 
PKC, protein kinase C; 
RIP1, receptor-interacting protein kinase 1; 
SMKIs, small-molecule kinase inhibitors; 
STE, homologs of yeast Sterile 7, Sterile 11, and Sterile 20 kinases; 
TK, tyrosine kinase; 
TKL, tyrosine kinase-like. 
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1. Introduction: kinase inhibition 
        Kinases transfer the gamma phosphate of ATP onto hydroxyl bearing substrates including 
proteins, lipids, and sugars, and are implicated in various cellular and extracellular activities 
(Johnson & Lewis, 2001). Overexpression and dysregulation of kinases are directly associated with 
many human diseases. Inhibition of kinases by small molecules can severely impair activation of 
crucial cellular signaling pathways. Initiated by pioneering work performed before the 1980s in the 
field, small molecule kinase inhibitors (SMKIs) entered the clinical stage in the 1990s, followed by 
a “sprouting decade of kinase inhibitors” research from 2001 to 2010 that was effectively kicked off 
by the FDA-approval of imatinib for the treatment of patients with chronic myeloid leukemia. As of 
July 2015, a total of 28 FDA-approved SMKIs (P. Wu et al., 2015a), together with a few more 
approved by drug administrations of other countries, are on the market. Encouraged by the success 
of SMKIs in clinical settings, kinases are now being intensively studied as key therapeutic targets in 
drug discovery (Fabbro et al., 2015), especially for the treatment of different types of human 
cancers (P. Wu et al., 2015b). In parallel, kinases have been indicated as potent therapeutic targets 
in targeting inflammatory diseases, cardiovascular diseases, diabetes, and also in neurological 
disorders, such as Alzheimer’s and Parkinson’s disease (Rask-Andersen et al., 2014).  
        However, a few factors collectively undermine the clinical applications of SMKIs. Many 
reported kinase inhibitors, including approved drugs, suffer from undesired selectivity profiles 
(Davis et al., 2011; Norman et al., 2012). Low specificity towards the target kinase and a lack of 
selectivity for structurally related kinase families may lead to side effects and off-target toxicity in 
clinical settings. In addition, the emergence of resistance due to site mutations in the ATP binding 
pocket also limits the use of SMKIs in cancer treatment. Since most developed SMKIs target the 
highly conserved ATP binding pocket, an alternative inhibition approach that targets other less-
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conserved allosteric pockets in the kinase domain, or other remote sites, is being actively pursued 
(Foda & Seeliger, 2014).   
2. Understanding allosteric kinase inhibitors 
        The majority of non-covalent SMKIs are ATP-competitive inhibitors, classified as either type I 
or type II inhibitors, by reference to the conformation of the highly conserved aspartate-
phenylalanine-glycine (DFG)-motif in the beginning of the activation loop in the C-lobe of the 
kinase domain (P. Wu et al., 2015a). Type I inhibitors, such as gefitinib (Iressa®), bind in the ATP 
pocket of the active kinase form with a “DFG-in” conformation. Type II inhibitors, such as imatinib 
(Gleevec®), bind in the hinge region of the ATP pocket and a less conserved allosteric region that 
is formed following the conformational change to the “DFG-out” motif, and stabilize the inactive 
form of the kinase. In contrast, allosteric inhibitors are defined as molecules that bind outside the 
ATP-binding pocket with no interaction with the hinge region that connects the N- and C-lobes of 
the kinase domain. Allosteric inhibitors can be classified as type III inhibitors, such as cobimetinib, 
which bind in an adjacent allosteric site that does not overlap with the ATP binding pocket/hinge 
region (Rice et al., 2012) (Fig. 1A), or type IV inhibitors, such as GNF2, which bind to an allosteric 
site that is distant from the ATP binding pocket (Zhang et al., 2010) (Fig. 1B). There are different 
definitions for other types of non-covalent SMKIs, which are referred to as type V inhibitors in this 
manuscript. Type V inhibitors include a small group of bivalent or bisubstrate inhibitors (Gower et 
al., 2014; Lamba & Ghosh, 2012), and a few inhibitors with hybrid type I and II features (Okamoto 
et al., 2015), which has also been referred to as type 1½ inhibitors (Zuccotto et al., 2010).  Even 
though most allosteric SMKIs are non-ATP competitive, as they bind into a site that does no 
overlap with the ATP-binding site, some allosteric SMKIs may still be ATP-competitive due to 
stabilization of the inactive conformation of their binding kinases (Cowan-Jacob et al., 2014).   
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Fig. 1. Two types of allosteric SMKIs. (A) Allosteric type III inhibitors bind into a pocket adjacent to the ATP-binding 
site, as exemplified by the cobimetinib-MEK1 co-crystal structure (PDB ID: 4AN2, 2.50 Å). The molecule bound in the 
ATP-binding pocket is phosphomethylphosphonic acid adenylate ester (PAAE); (B) Allosteric type IV inhibitors bind 
in a pocket distal to the ATP-binding site, as exemplified by the GNF2-Abl co-crystal structure (PDB ID: 3K5V, 1.74 
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Å). The molecule bound in the ATP-binding pocket is imatinib. The SH3 domain, SH2 domain, and the linker between 
SH2 and N-lobe are not included in the GNF2-Abl co-crystal structure with imatinib. Hydrogen bond interactions are 
indicated with red dotted lines, molecules bound in the ATP-binding pocket are shown with yellow backbones, 
allosteric inhibitors are shown with magenta backbones, and the residues of the DFG-motif are shown with white 
backbones. 
        The field of allosteric kinase inhibition has evolved rapidly in the past few years with the 
FDA-approval of trametinib as the first allosteric SMKI, the progression of more than 10 other 
allosteric inhibitors of MEK and Akt in clinical trials, and examples of allosteric inhibitors of 
LIMK2, PAK, IRE1, and RIP1 being reported for the first time. 
        The comparatively low sequence homology of allosteric sites provides unique opportunities for 
more specific inhibition and minimal off-target pharmacology (Fang et al., 2013). Other advantages 
of allosteric inhibitors over traditional ATP-competitive type I and II inhibitors include the potential 
to overcome mutation-associated drug-resistance, especially mutations in the ATP-binding site that 
confer resistance to almost all related ATP-competitive inhibitors, such as the frequently occurring 
T315I mutations in the gatekeeper residue Abl (Gibbons et al., 2012) In addition, SMKIs may not 
need to exhibit nanomolar affinity to compete with the high intracellular ATP concentrations, 
making it easier to identify weak binding inhibitors, ranging from fragments to hit and lead 
compounds, and treatment of indications beyond cancer may be feasible. Furthermore, allosteric 
SMKIs can find utility as selective chemical probes to facilitate mechanistic studies on molecular 
function. With these attractive features, allosteric inhibitors are now being extensively studied as a 
new generation of SMKIs. 
        As previous articles have analyzed the structural basis (Fang et al., 2013), and discussed the 
potential and opportunities (Cowan-Jacob et al., 2014), for allosteric inhibition, this review will 
highlight recent development on small-molecule allosteric inhibitors that have already progressed in 
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clinical trials and inhibitors that were revealed in the past three years. Inhibitors that disrupt protein-
protein interactions are not covered in this discussion. 
 3. Allosteric serine/threonine kinase inhibitors 
        The signaling cascades of Ras-Raf-mitogen/extracelluar signal-regulated kinase (MEK) 
pathway (Samatar & Poulikakos, 2014) and phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian 
target of rapamycin (mTOR) pathway are among the most frequently dysregulated signaling 
networks in human malignancies (Fruman & Rommel, 2014; Houédé & Pourquier, 2015). A large 
number of structurally diverse small molecules have been reported as inhibitors of key kinases 
through both pathways. The serine/threonine kinases MEK and Akt are among the most thoroughly-
investigated targets for which allosteric inhibitors have been developed (Fasano et al., 2014).   
 3.1 MAPKK and MAPK inhibitors 
        Mitogen/extracellular signal-regulated kinase (MEK), also known as mitogen-activated protein 
kinase kinase (MAPKK), is a dual specificity threonine/tyrosine kinase that plays a critical role in 
the Raf-Ras-MEK signaling pathway.  A selection of highly selective and potent allosteric non-ATP 
competitive MEK inhibitors are currently in clinical trials of different phases for the treatment of 
non-small cell lung cancer (NSCLC) (Zhao & Adjei, 2014). 
        The MEK1/2 inhibitor trametinib (1, Mekinist®, originally developed by GlaxoSmithKline, 
but owned by Novartis starting from May 2015) is the first and only approved allosteric SMKI, 
whose structural-activity relationship and pharmacological profile have been widely studied (Abe et 
al., 2011). Trametinib was approved by FDA in May 2013 as a single-agent for the treatment of 
patients with either B-Raf V600E or V600K mutated metastatic melanoma. Most common adverse 
reactions of trametinib in more than 20% of patients are rash, diarrhea, and lymphedema, which are 
also common adverse reactions for many other approved SMKIs. To overcome the observed 
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progression using single-agent trametinib, which usually occurs within 7 months, combination 
strategies using the B-Raf inhibitor dabrafenib was evaluated and shown to delay the emergence of 
resistance and significantly improve survival without increased overall toxic effects (Long et al., 
2014; Robert et al., 2015). FDA approved the combination of dabrafenib and trametinib for the 
treatment of B-Raf V600E/K mutated metastatic melanoma in January 2014. 
 
Fig. 2. Approved and clinically investigated allosteric MEK1/2 inhibitors. 
        Diarylamine compounds comprise for a major class of allosteric MEK1/2 inhibitors (Rice et al., 
2012). Cobimetinib (2) is being studied in combination with the FDA-approved B-Raf inhibitor 
vemurafenib for the treatment of B-Raf V600E/K mutation-positive advanced melanoma 
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(Hatzivassiliou et al., 2013), which has showed a median progression-free survival of 9.9 months 
compared to 6.2 months using vemurafenib alone, although at the cost of increased toxicity in terms 
of liver lab value abnormalities, elevated level of creatine phosphokinase, and diarrhea 
(NCT02427893) (Larkin et al., 2014). This application has been granted a priority review by FDA, 
and a decision on approval is expected by November 11, 2015.   
        Selumetinib (3, AstraZeneca) is currently in various active clinical trials on advanced NSCLC 
(Jänne et al., 2013) and soft-tissue sarcomas (Eroglu et al., 2015), while a phase III study using 75 
mg of selumetinib in combination with dacarbazine as first systemic therapy in patients with 
metastatic uveal melanoma failed to improve progression-free survival compared to dacarbazine 
alone (NCT01974752). 
        Other advanced diarylamine compounds with structures closely related to that of cobimetinib 
and selumetinib include binimetinib (4), pimasertib (5), refametinib (6), PD184352 (7), and 
PD0325901 (8) in phase II trials, and RO4987655 (9), TAK-733 (10), and GDC-0623 (11) in phase 
I trials. Phase I compound RO5126766 (12) represents another series of allosteric MEK inhibitors 
containing a chromen-2-one scaffold (Samatar & Poulikakos, 2014) (Fig. 2).  
        Recent examples of preclinical MEK inhibitors include a series of chromone-based structures, 
such as PD98059 (13) and compound 14, which showed an IC50 value of 30 nM against MEK1 
(Redwan et al., 2014) (Fig. 3). 
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Fig. 3. Preclinical allosteric inhibitors of MAPKK and MAPK. 
        Mitogen-activated protein kinases (MAP kinases or MAPKs) p38 and c-Jun N-terminal protein 
kinases (JNKs) are downstream effectors of MAPKK. Biphenyltetrazole compound 15 (inactivated 
JNK1, Kd: 11 μM) , which binds into a pocket located in the MAP insert region that is distant from 
the ATP-binding pocket, was identified as a type IV allosteric inhibitor of JNK1 by an affinity-
based screening approach. The same study unfolded compound 16 as a selective p38α inhibitor 
(p38α, IC50: 1.2 μM; p38β, γ, and δ, IC50: > 40 μM), which binds into a distal allosteric pocket in 
the C-lobe of the p38 kinase domain (Comess et al., 2011). A series of natural product derived 
fragments with a cytisine or sparteine scaffold were recently identified as inhibitors that exclusively 
bind into the DFG-out pocket of p38α with weak potencies and low ligand efficiencies  (Over et al., 
2013). In addition, several pyrazolylureas have been previously reported as potent allosteric p38 
inhibitors (Regan et al., 2003). 
3.2 Akt inhibitors  
        The serine/threonine kinase Akt, also known as protein kinase B (PKB), is an important knot 
in the PI3K/Akt/mTOR signaling cascade, which is tightly associated with cell proliferation, 
survival, migration, angiogenesis and many other biological activities, especially processes that are 
directly associated with tumor genesis and progression (Fruman & Rommel, 2014; P. Wu et al., 
2009). Reported ATP-competitive Akt inhibitors have shown poor selectivity against other kinases, 
especially the closely related ones in the kinase family containing protein kinases A, G, and C 
(AGC), let alone the three highly homologous isoforms of Akt (Lindsley, 2010). Akt inhibition is 
still a challenging issue, as illustrated by the fact that only few lead candidates have been identified 
so far, despite considerable efforts in both academia and the pharmaceutical industry.  
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        The best characterized allosteric inhibitor of Akt is the [1,2,4]triazolo[3,4-f][1,6]naphthyridin-
3-one compound MK-2206 (17) (Hirai et al., 2010), which targets a unique allosteric pocket at the 
interface of the catalytic kinase domain and the regulatory pleckstrin homology (PH) domain of the 
inactive conformation of Akt. Compound MK-2206 is currently under investigation in various 
phase I and II studies on breast cancer, NSCLC, nasopharyngeal carcinoma, colon/rectal and other 
cancers, with a maximum tolerated dose of 60 mg on alternate days or a weekly intermittent dose of 
200 mg (Yap et al., 2014). 
 
Fig. 4. Allosteric Akt inhibitors. 
        Based on the structural and binding features of MK-2206, a few more allosteric inhibitors, 
such as compounds 18 (Akt1, IC50: 58 nM, Akt2, IC50: 0.21 μM, Akt3, IC50: 2.1 μM) (W.-I. Wu et 
al., 2010) and 19 (Akt1, IC50: 5 nM, Akt2, IC50: 18 nM, Akt3, IC50: 0.17 μM) (Ashwell et al., 2012) 
(Fig. 4), have been identified and co-crystallized with full-length Akt (Fig. 5). Compound 20 was 
very recently identified as a potent allosteric and covalent Akt inhibitor with an IC50 value of 0.2 
nM against Akt1. The diphenylnaphthyridinone scaffold of compound 20 fits into the MK-2206 
binding site, and its terminal electrophile forms covalent bonds with Cys296 or Cys310 located on 
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the flexible activation loop of Akt. At 1 μM concentration, compound 20 showed significant 
inhibitory potency (>80%), exclusively against Akt1, Akt2, and Akt3, in a kinase profiling assay. In 
addition, compound 20 was also shown to be a cell-permeable effector of Akt in gastrointestinal 
stromal tumor cells (Weisner et al., 2015).  
 
Fig. 5. Allosteric inhibitors of Akt bind in a pocket at the interface of the kinase domain and the PH domain, 
exemplified by the 19-Akt co-crystal structure (PDB ID: 4EJN, 2.19 Å). The inactive “DFG-motif out” conformation 
(detailed view) is stabilized by allosteric inhibition. Hydrogen bond interactions are indicated with red dotted lines, 
allosteric inhibitor compound 19 is shown with magenta backbone, the residues of the DFG-motif are shown with white 
backbones, and the exposed cysteine residues for covalent inhibition with molecules incorporating chemically active 
Michael acceptor electrophiles are shown with purple backbones. 
3.3 CDK inhibitors 
        Following decades of intensive investigation centered around cyclin-dependent kinase (CDK) 
inhibitors, the CDK4/6 inhibitor palbociclib (Ibrance®, Pfizer) was approved as an ATP-
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competitive inhibitor for the treatment of breast cancer in February 2015 (Lu & Schulze-Gahmen, 
2006). The reservoir of reported CDK inhibitors includes a large number of other potent ATP-
competitive inhibitors (Pitts et al., 2014), while the majority of these compounds have shown 
undesired selectivity and toxicity. Several allosteric inhibitors with micromolar inhibitory potency 
against CDK2 were identified through a virtual screening campaign combined with docking 
analysis. Representative compound (21, Fig. 6) binds into an allosteric pocket of CDK2 formed 
following displacement of the αC-helix, and showed an IC50 value of 4 μM against breast cancer 
cell lines (Rastelli et al., 2014).      
        A pyrazolylurea compound (22, Fig. 6), identified in a fragment-based strategy, has been 
shown to bind deep inside the DMG-out pocket (equivalent to DFG-out pocket of other kinases) of 
CDK8/CycC complex with a Kd value of 3.24 μM, without interacting with the hinge region of 
CDK8 (E. V. Schneider et al., 2013). Compounds sharing the pyrazolylurea scaffold have also been 
reported as allosteric inhibitors of the p38 MAPK (Regan et al., 2003) and tyrosine kinase cSrc 
(Simard, Kluter, et al., 2009). 
 
Fig. 6. Allosteric CDK inhibitors. 
3.4 LIMK inhibitors 
        A series of N-phenylsulfonamide compounds, such as compounds 23 (IC50: 92 nM), 24 (IC50: 
39 nM) and 25 (IC50: 3 nM) (Fig. 7), were recently reported as the first known type III inhibitors of 
tyrosine-like kinase (TKL) LIM-kinase (LIMK)2. Screening assays against selected kinases from 
18 
 
TKL, TK, AGC, CAMK, homologs of yeast Sterile 7, 11, 20 kinases (STE), and containing CDK, 
MAPK, GSK3, CLK (CMKC) families, showed that compound 24 was highly selective for LIMK2, 
even against the closely related LIMK1. A co-crystal structure of 25 and LIMK2 showed binding 
away from the hinge region and occupation of the allosteric hydrophobic pocket formed through the 
DFG-out conformational change instead (Goodwin et al., 2015). 
 
Fig. 7. Allosteric LIMK2 inhibitors. 
3.5 PKC inhibitors 
        A series of 1,3,5-trisubstitued pyrazolines, such as compound 26 (IC50: 0.3 μM) (Fig. 8), was 
recently developed as selective allosteric inhibitors of the atypical isoform of the protein kinase C 
(PKC) family PKCζ, which is being studied as a therapeutic target in allergic and inflammatory 
disease (Diaz-Meco & Moscat, 2012). Compound 26 was assumed to bind with the PDK1-
interacting fragment (PIF) pocket, also known as hydrophobic motif pocket of PKCζ, and did not 
show significant inhibition against any other PKC isoforms and some related kinases in the AGC 
family at a concentration of 10 μM (Abdel-Halim et al., 2014). 
 
Fig. 8. Allosteric PKCζ inhibitor. 
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3.6 PDK1inhibitors 
        Phosphoinositide-dependent kinase-1 (PDK1) masters the activation of more than 20 
downstream AGC kinases such as Akt and PKC and has been validated as a potential target for 
anticancer therapy. The PIF binding pocket is a αC-helix patch, which is a functionally conserved 
allosteric site on the AGC family of serine/threonine kinases and various other serine/threonine and 
tyrosine kinases. Several diaryl sulfonamides were screened as allosteric inhibitors of PDK1 by 
using a PIF-site directed chemical screening approach involving a fluorescence polarization 
competitive binding assay. Representative compounds RS1 (27) and RS2 (28) showed Kd values of 
1.5 and 9 μM (Fig. 9). RS1 is able to freely diffuse into cells and enhance the effect of ATP-
competitive inhibitors of PDK1 to block activation of S6K1 and Akt in human embryonic kidney 
cells (Rettenmaier et al., 2014).  
 
Fig. 9. Allosteric PDK1 inhibitors. 
3.7 RIP1 inhibitors 
        The receptor-interacting protein kinase 1 (RIP1) is a critical upstream signaling molecule in 
inflammatory signaling and cell death pathways including apoptosis and necrosis factor α induced 
necroptosis (Ofengeim & Yuan, 2013). A series of necrostatin analogues that bind in a hydrophobic 
pocket formed due to the DFG-out pocket of the inactive conformation of RIP1 are among few 
reported examples of allosteric RIP1 inhibitors. Representative compound Nec-1a showed IC50 
values of 0.3 μM, 1.2 μM, and 3.2 μM, against wild-type RIP1, RIP1 S161A mutant, and RIP1 
S161E mutant, respectively (Xie et al., 2013) (Fig. 10).  
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Fig. 10. Allosteric RIP1 inhibitor. 
3.8 PAK inhibitors 
        Starting from a fragment-based screening hit, a series of dibenzodiazepine compounds, such as 
compounds 30 (IC50: 18 nM) and 31 (IC50: 5 nM) (Fig. 11), were obtained as highly selective p21-
activated kinase 1 (PAK1) inhibitors that bind in an allosteric pocket formed by the gatekeeper 
residue of PAK1 (Met344), αC-helix, and the DFG-out conformation. The optimized compound 31 
demonstrated an exceptional selectivity profile against other known kinases, including PAK2 that 
shares 93% kinase domain homology with PAK1. In addition, compound 31 showed good 
physicochemical properties and no significant CYP450s inhibition, albeit its short half time of 3.5 
min in rat liver microsomes indicated limitations for further in vivo application (Karpov et al., 
2015). 
 
Fig. 11. Allosteric PAK inhibitors. 
3.9 IRE1 inhibitors 
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        The inositol requiring enzyme 1 (IRE1), a serine/threonine kinase that possesses endonuclease 
activity, has been pursued as an anticancer target because of its role in maintaining protein synthesis 
homeostasis through the unfolded protein response cascade (Walter & Ron, 2011). Harrington et al. 
reported the identification of selective inhibitors of IRE1α, such as the naphthalenylarylsulfonamide 
32 (IC50: 14 nM, Fig. 12), which binds in an allosteric pocket formed following the αC-helix shift of 
IRE1α (PDB ID 4U6R, 2.5 Å). However, the fact that no significant cytotoxicity was observed 
when compound 32 was screened against more than 200 tumor cell lines suggests that selective 
IRE1α inhibitors may not be efficient antitumor agents (Harrington et al., 2015).  
 
Fig. 12. Allosteric IRE1 inhibitor. 
3.10 CHK1 inhibitors 
        Checkpoint kinase 1 (CHK1), a serine/threonine kinase belonging to the calcium/calmodulin-
dependent protein kinase (CAMK) family, plays a critical role in protecting cells from DNA 
damage and regulating various mechanisms of DNA repair. Thus, the development of small 
molecule CHK1 inhibitor as chemopotentiators and single-agent therapies has attracted 
considerable interest (McNeely et al., 2014). Among the reported inhibitors of CHK1 are a few 
molecules, represented by the carbamate compound 33, semicarbazide compound 34, and 
quinazolinone compound 35 (Fig. 13), which bind in an allosteric pocket adjacent to the peptide 
substrate binding site of CHK1 (Converso et al., 2009; Vanderpool et al., 2009). All these allosteric 
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inhibitors were revealed in 2009, and no recent examples of new allosteric CHK1 inhibitors have 
been reported since then.   
 
Fig. 13. Allosteric CHK1 inhibitors. 
4. Allosteric tyrosine kinase inhibitors 
4.1 Abl inhibitors 
         GNF-2 (36) was discovered by a phenotypic screening and demonstrated to bind to the 
myristoyl pocket of the C-lobe of the kinase domain (Fig. 1b), wand stands out as the first identified 
type IV inhibitor of Abl. A series of 1,3,4-thiadiazole compounds were recently reported as 
promising Abl inhibitors. A kinetic study showed that the lead compound BO1 (37) inhibited Abl 
T315I in an ATP-independent manner (Fallacara et al., 2014). Pyrazolo[3,4-d]pyrimidine is a 
common scaffold found in small molecules with inhibitory activities against PI3Ks, Src, Abl, and 
several other kinases (Schenone et al., 2014). A target-based approach performed by the same group 
provided a library of highly functionalized pyrazolo[3,4-d]pyrimidines and led to the discovery of a 
series of potential allosteric inhibitors of Abl. The most potent compound 38 showed an IC50 value 
of 3.16 μM against Abl T315I, which was independent of the concentration of ATP and the peptide 
substrate (Vignaroli et al., 2014) (Fig. 14). 
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Fig. 14. Allosteric tyrosine kinase inhibitors discussed in this paper. 
4.2 FAK inhibitors 
        By functioning as a switch in signaling transduction, focal adhesion kinase (FAK) has been 
correlated with metastatic disease and studied as a potential anticancer target (Lee et al., 2015). 
Tricyclic sulfonamide compound 39 (FAK kinase domain IC50: ~1 μM, and FAK full length IC50: 
3-9 μM) was identified as a selective FAK inhibitor that binds in an allosteric pocket of the C-lobe. 
In contrast, compound 40 without the N-ethyl substituent is a dual ATP competitive and non-ATP 
competitive inhibitor that showed IC50 values ranging from 1 to 10 μM against several kinases in a 
profiling assay, and it showed equivalent inhibitory potency against phosphorylated and 
unphosphorylated FAK (Iwatani et al., 2013) (Fig. 14). 
4.3 ITK inhibitors 
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        Interleukin-2-inducible T-cell kinase (ITK) is an important target for autoimmune and 
inflammatory disease. Started from a naphthalenylpyrazole hit 41 (ITK kinase domain, IC50: 0.11 
μM; ITK full length, IC50: 12.4 μM) that binds simultaneously at the ATP site and an adjacent 
allosteric site, compound 42 (ITK kinase domain, IC50: 20 nM; ITK full length, IC50: 4.99 μM) was 
identified as the first allosteric inhibitor of ITK that occupies a pocket adjacent to the ATP binding 
pocket. It is worth mentioning that surface plasmon resonance and NMR studies indicated a low 
binding affinity of compound 42 in the ATP binding pocket. In contrast to the promiscuous kinase 
inhibitor 41, compound 42 showed high selectivity for ITK in binding assays, which might be 
explained by the steric clash between the isopropyl substituent of 42 and the glycine loop of the 
ATP binding site that attenuate binding with other kinases. In addition, compound 42 inhibited 
cytokine production in human whole blood and T-cells (Han et al., 2014).  
4.4 IGF-1R inhibitors 
        High-throughput screening campaigns against compound collections of Merck Serono led to 
the identification and development of a series of bisindole derivatives as allosteric inhibitors of 
receptor tyrosine kinase insulin-like growth factor-1 receptor (IGF-1R). Representative compound 
43 occupies a pocket adjacent to the ATP-binding pocket and the activation loop (PDB ID: 3LW0, 
1.79 Å), and showed an IC50 value of 0.4 μM against IGF-1R (Heinrich et al., 2010). 
5. Other allosteric kinase inhibitors 
5.1 PI3K inhibitor 
        Lipid kinases PI3Ks have been extensively studies as a key knot along the PI3K/Akt/mTOR 
pathway that is frequently deregulated in human cancers. Among the numerous inhibitors 
developed for the isoforms of PI3K, a group of arylmorpholine or morpholinochromone derivatives 
and analogues stands out (Houédé & Pourquier, 2015; P. Wu & Hu, 2012; P. Wu et al., 2012). One 
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such compound, the pan-PI3K inhibitor PIK-108 (44, Fig. 15), has been shown to bind in an 
allosteric site close to the mutation hotspot of H1047R in the PI3Kα C-lobe, in addition to its 
binding at the ATP-binding pocket (Hon et al., 2012). 
5.2 mTOR inhibitors 
        mTOR is a member of a group of large, atypical serine/threonine kinases named as 
phosphatidylinositol 3-kinase-like protein kinases (PIKK) that share high sequence similarity with 
PI3Ks. Being another important knot along the PI3K signaling pathway, mTOR has been intensely 
investigated as an anticancer target. Besides ATP-competitive small-molecule mTOR inhibitors and 
dual PI3K/mTOR inhibitors, a series of macrocyclic rapamycin analogs, or rapalogs, including 
FDA-approved everolimus and temsirolimus, which allosterically inhibit mTORC1, were among 
the successful examples of approved agents targeting the PI3K pathway (P. Wu & Hu, 2010).   
5.3 IKKs inhibitors 
        IκB kinases (IKKs) are key regulators in the NF-κB pathway that controls transcription, cell 
survival, immune responses, thus small IKK inhibitors have been studied as potential therapeutics 
for inflammatory disorders and cancer (DiDonato et al., 2012). Early reported allosteric inhibitor of 
IKKs includes BMS-345541 (45, IKKα, IC50: 4 μM, IKKβ, IC50: 0.3 μM) (Burke et al., 2003) (Fig. 
14). Besides synthetic small molecule inhibitors, the natural product ainsliadimer A (46) was 
recently identified as a potent irreversible covalent and allosteric inhibitor of IKKβ (Dong et al., 
2015). 
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Fig. 15. Other allosteric kinase inhibitors. 
6. Perspectives 
        Since active kinases are used in most screening assays, novel assays are needed to identify 
allosteric inhibitors. Most reported allosteric SMKIs were discovered by serendipity and confirmed 
by a co-crystalized structure with corresponding kinases, and although assays for the detecting of 
allosteric binding are gradually emerging (Fang et al., 2015) (R. Schneider et al., 2012; Simard, 
Getlik, et al., 2009; Taipale et al., 2013), a systematic approach for the identification of allosteric 
SMKIs is still missing. Structural information based on co-crystallization provides the most 
convincing evidence for allosteric inhibitory binding. However, the generation of a co-crystal 
structure for SMKIs with kinases may not be a practical solution for every potential allosteric 
inhibitor in question, and it is advisable to examine the possibility of any allosteric inhibition, such 
as by docking simulations using the whole kinase domain. 
        Other frequently debated topics centered on allosteric SMKIs deserve attention. Firstly, the 
main advantage offered by allosteric inhibition is the potential to achieve high selectivity and 
overcome drug resistance. Although resistance to SMKIs occurs frequently within the hinge region, 
it also happens in other parts of the kinase domain or even beyond the kinase domain. Mutation-
related resistance is likely to occur in allosteric sites due to the fact that they are not as essential for 
kinase functions as the ATP binding site. 
        Secondly, due to the hydrophobic properties of most allosteric pockets, the majority of 
allosteric inhibitors are lipophilic compounds with poor solubility and bioavailability. An additional 
solubilizing group might be needed to improve the pharmacokinetic properties of these compounds, 
and salt forms can be formulated for oral administration in clinical use. 
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        Third, further investigation on the biological and structural basis is needed to provide crucial 
information for future design of optimal SMKIs. One major challenge stems from the inherent 
flexibility of most kinase structures. For a limited number of kinases, both the kinase off-state 
structure and kinase-SMKI complex structure have been successfully solved, and this renders a 
direct comparison possible, thus identifying any SMKI-induced changes. For the majority of 
kinases targeted so far, most crystal structures solved are the ones complexed with SMKIs. The fact 
that some of the allosteric pockets are likely to engage in protein-protein and protein-peptide 
interactions further complicates the issue.  
        In terms of therapeutic indication, the lack of selectivity of most SMKIs generally does not 
hamper cancer treatment. However, this issue will probably translate into unacceptable side effects 
in therapeutic areas outside oncology, especially in chronic diseases, for which selective allosteric 
SMKIs may be used as most promising lead candidates. It is a widely accepted notion that 
combination strategies, such as the combination of targeted drugs with traditional chemo- or 
immunotherapy, are beneficial in cancers treatment. Thus, it is reasonable to expect that 
combination therapy strategies with all types of SMKIs, including ATP-competitive inhibitors, 
allosteric inhibitors, and covalent inhibitors, might lead to complete kinase suppression and 
favorable anticancer outcomes in clinical settings within oncology. 
          
7. Conclusion 
       With the prospect of achieving high selectivity, allosteric inhibitors, as exemplified in this 
manuscript, offer means of kinase inhibition complementary to existing inhibitors targeting the 
highly-conserved ATP binding pockets. The allosteric pockets utilized by type III inhibitors usually 
involve the structural arrangement of the DFG-motif at the beginning of the activation loop and/or 
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the displacement of the conserved structural αC-helix at the N-lobe of the kinase domain. Type IV 
inhibitors that bind into distinct allosteric pockets distal from the ATP site have been less studied. 
Research on allosteric SMKIs is currently on the frontline of kinase research, as demonstrated by 
the approval of trametinib in 2013, the progression of more than 10 advanced molecules in clinical 
trials of different phases, and a burgeoning pipeline of preclinical allosteric SMKIs with excellent 
specificity and potency profiles. In spite of the advantages offered by allosteric inhibitors, the field 
remains impacted by some controversial issues that need to be appropriately addressed to complete 
the process from laboratory bench to patients’ bedside. After all, identifying an allosteric SMKI is 
easier than making a clinically approved SMKI. 
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